Local control was similar across proton, photon and stereotactic radiotherapy for grade 1 meningioma
Five-year local control exceeded 89% across proton, photon and stereotactic approaches, with no significant modality effect in meta-regression.
Five-year local control exceeded 89% across proton, photon and stereotactic approaches, with no significant modality effect in meta-regression.
Individual target optimization lowered normal-brain V12 and improved dose gradients while maintaining over 99% coverage, at the cost of higher monitor units.
Single-fraction 22 Gy SRS achieved higher one-year local control than 20 Gy, although retrospective dose selection creates important confounding.
A 1 mm symmetric MLC closing reduced minimum GTV dose by 25%, while translations caused cumulative target undercoverage.
Preoperative SRS/FSRT completed local therapy 22.5 days sooner than postoperative treatment, with similar 30-day morbidity; oncologic outcomes remain pending.
A single knowledge-based model generated comparable ocular plans for 25 Gy once, 42 Gy in three fractions and 50 Gy in five.
Brain metastasis contours showed generally high agreement, although lesion volume, oedema and magnetic resonance imaging field strength influenced variability.
A case report describes pathology-confirmed late radiation necrosis after stereotactic radiosurgery, with radiographic progression temporally associated with repeated COVID-19 vaccination.
Aperture-enhanced proton stereotactic radiosurgery reduced normal brain dose compared with photon plans in most cerebral arteriovenous malformation cases.
A case report linked high-dose Boswellia serrata use for radiation necrosis with reversible acute kidney injury.
After 66% of couch-angle changes, motion exceeded tolerance, and 0.5-millimetre and 0.5-degree errors reduced near-minimum target dose by 7.6%.
No single patient-specific quality assurance method covered all stereotactic radiotherapy risks, supporting combinations of measurement, independent calculation, imaging, and monitoring.